Specialty Pharmacy

The ADMIRAL trial found that gilteritinib is a significant addition to the treatments available for patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss why data standardization is important in specialty pharmacy and how technology plays into it during the NASP Annual Meeting in Washington, DC.

Top news of the day from across the health care landscape.

Study shows a significantly greater proportion of patients with Crohn disease who were administered ustekinumab every 8 weeks achieved a histologic response.

Top news of the day from across the health care landscape.

Pegfilgrastim-bmez (Ziextenzo, Sandoz), a biosimilar to pegfilgrastim (Neulasta), is indicated to decrease the incidence of febrile neutropenia, a serious adverse effect of chemotherapy.

Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

Jesse C. Dresser, Esq explains how specialty pharmacists can educate and inform legislators on PBM reform at the NASP Annual Meeting in Washington, DC.

Dicyclomine Hydrochloride Injectable is the generic version of Bentyl from Allergan and is used to treat functional bowel or irritable bowel syndrome.

Omeprazole magnesium, amoxicillin, and rifabutin (Talicia, RedHill Biopharma) is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Top news of the day from across the health care landscape.

Advancements in the understanding of asthma pathophysiology has led to the discovery of defined asthma phenotypes and targeted interventions involving novel biologic therapies.

Three complement genes identified in a new study may serve as markers for monitoring and predicting the progression and severity of multiple sclerosis.

Texas oncologist Stephen Hahn, MD, is expected to receive the Trump administration’s nomination for the role of FDA Commissioner, a move that had been anticipated by federal insiders.

Top news of the week from Specialty Pharmacy Times.

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

Top news of the day from across the health care landscape

The Ensuring Seniors Access to Local Pharmacies Act, which was recently reintroduced, would allow more “preferred” pharmacies in medically underserved areas.

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

Lumacaftor-ivacaftor (Orkambi) improves lung health in patients with cystic fibrosis who tolerate the treatment, but discontinuation rates may pose a risk of deterioration.

Top news of the day from across the health care landscape

A new computer method could help reveal the origins of Crohn disease and improve early diagnosis and accuracy.

Early treatment with lenalidomide in patients with smoldering multiple myeloma may help delay onset of myeloma-related bone and organ damage.

The FDA Drug Shortages Task Force addressed the root causes of drug shortages and proposed potential solutions.

Top news of the day from across the health care landscape

Men treated with stereotactic ablative radiotherapy found to live significantly longer without any detectable disease progression compared with patients who received no additional treatment.

Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.

A study assessing melanoma cell variability indicates that identifying differences in cell states can be leveraged to improve patient outcomes.

An ongoing phase 2 study is evaluating SY-1425 plus azacitadine in newly-diagnosed unfit patients with acute myeloid leukemia.

Study suggests that men who use assisted reproduction techniques may benefit from early screening and long-term monitoring for prostate cancer.